Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Audio Recap: Timely Treatment for COVID-19

Source: Timely Treatment for COVID-19
Hear expert insights on therapies under evaluation or authorized for the treatment of patients with COVID-19, including which antivirals to use and when, and how to operationalize administration of anti–SARS-CoV-2 monoclonal antibodies in the outpatient setting.
Lynora Saxinger, MD, FRCPC, CTropMed
Released: October 11, 2021

During this episode, Lynora Saxinger, MD, FRCPC, CTropMed, updates listeners on the latest Emergency Use Authorizations and guideline recommendations for optimal clinical management of COVID-19. Gain practical insights on patient identification, risk stratification, and treatment.

Key points include:

  • Treatment of COVID-19 can be broken into antiviral and immune-modulating therapies
    • Each agent should be used at the correct disease stage to maximize benefit
  • Antiviral medications and mAbs show the greatest promise early during COVID-19, before the host immune response is mounted
  • Passive immunization with mAbs can prevent infection and severe disease—and mortality—if given early to hospitalized persons
  • Operational challenges to using these medications exist, but given the epidemic of unvaccinated persons, these treatments become increasingly relevant to reduce burden on healthcare systems

Information on this Educational Activity

Faculty

Lynora Saxinger, MD, FRCPC, CTropMed

Cochair, Scientific Advisory Group
Alberta COVID-19 Emergency Coordination Centre
Associate Professor
Division of Infectious Diseases
Department of Medicine
University of Alberta
Edmonton, Alberta, Canada

Lynora Saxinger, MD, FRCPC, CTropMed, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Related Content

Expert faculty provide a comprehensive overview of current landscape of outpatient COVID-19 management strategies, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE

Renslow Sherer, MD person default Trinh P. Vu, PharmD, BCIDP Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 22, 2022 Expired: November 21, 2023
Introduction
Current State of COVID-19
Testing and Risk Stratification
Guideline Recommendations and Treatment Selection
Clinical Trials of COVID Treatments
Long COVID
Question and Answer Session

Dr Jason Gallagher and Dr Emily Heil on COVID-19 antivirals for nonhospitalized patients and COVID-19 rebound, from Clinical Care Options (CCO)

person default Jason Gallagher, PharmD Emily Heil, PharmD, MS, BCIDP, AAHIVP Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: November 22, 2022 Expired: November 21, 2023

Clinical Care Options (CCO) podcast with Dr Princy N. Kumar and Dr Paul E. Sax on key COVID-19 data from IDWeek 2022

Princy N. Kumar, MD, FIDSA, MACP Paul E. Sax, MD Released: November 18, 2022

Dr Alicia Lichvar: importance of COVID-19 prevention in patients with immunocompromise, from Clinical Care Options (CCO)

person default Alicia Lichvar, PharmD, MS, BCPS, BCTXP Released: November 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings